Cyclacel Pharmaceuticals (NASDAQ:BGMS) Trading Down 19.2% – Here’s What Happened

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS)’s share price was down 19.2% on Thursday . The stock traded as low as $0.9503 and last traded at $0.9537. Approximately 135,266 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 167,471 shares. The stock had previously closed at $1.18.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Trading Down 19.2%

The company has a market capitalization of $5.26 million, a price-to-earnings ratio of -0.21 and a beta of -0.54. The company’s 50 day simple moving average is $1.00.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its quarterly earnings data on Monday, March 30th. The company reported ($2.21) EPS for the quarter. The company had revenue of $0.67 million during the quarter.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.